From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
PHOENIX, Ariz.– Humabiologics Inc., a regenerative medicine company founded by scientists and tissue industry experts, announced today it has successfully raised $1 million in seed funding.
IMNA Solutions announced today that it has appointed Russ Yelton, President/CEO of Yelton and Associates and Chairman of The Board of Trustees of AZAdvances to its board of directors
Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer
Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone Data Add to Body of Evidence from Prior Studies Demonstrating Benefit of Remdesivir in Hospitalized Patients with COVID-19
- Digital RESI – Three Day Conference
- 06/08/2020 - 06/10/2020
- NCCN Oncology Policy Summit: Accelerating Advances in Cancer Care Research: A Look Back at the 21st Century Cures Act in 2020
- AZBioPEERS: Building a Company that is Investment Ready
- Real World Evidence - Meet the future with confidence.
- AZBioPEERS: What is my company worth? Establishing a valuation